Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Abstract Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) is a dose-finding phase I and a randomized phase II, open-label trial evaluating if targeting the immunosuppressive adenosine pathw...

Полное описание

Библиографические подробности

Главные авторы:	Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Nature Portfolio 2023-11-01
Серии:	Nature Communications
Online-ссылка:	https://doi.org/10.1038/s41467-023-42744-y
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!